Generics Dispute EU-India Trade Negotiations - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Generics Dispute EU-India Trade Negotiations
The recent India–EU summit was expected to bring news about the upcoming Free Trade Agreement between the EU and India; however, a dispute regarding the supply of generic drugs from India to developing countries has taken centre stage.

Pharmaceutical Technology Europe
Volume 23, Issue 2


1. European Commission, "Bilateral Relations: India" (2010).

2. Securing Pharma, "EU aims to appease India with softened customs law" (2010).

3. Business Standard, "India, EU expect FTA by spring of 2011" (2010).

4. Indian Drug Manufacturers' Association (2010).

5. Médecins Sans Frontières, "At EU-India Summit, European Negotiators Urged Not to Block Access to Affordable Medicines" (2010).

6. AIDS News, "India Changes Patent Law to Meet WTO Treaty, Making New Medicines Less Available to Most Citizens, Other Countries" (2004).

7. Henry J. Kaiser Family Foundation, "India's Trade Minister Says EU Will To Take Steps To Prevent Seizure Of Generic Medicines" (2010).

8. DNA India, "Netherlands assures India to sort out drug seizure issue" (2009).

9. EU Business, "Brazil, India take EU to WTO over generic drug seizures" (2010).

10. The Economic Times, "Indian generics to be safe from seizure while passing through EU" (2010).

11. HM Revenue & Customs, "European Community (EC) legislation. HMRC Reference: Notice 34" (2010).

12. Indian Express, "Indian pharma cos shun EU, route goods via SA ports" (2010).

13. BBC News, "India-EU generic drug row 'resolved' at Brussels summit" (2010).

14. Europe! Hands off our medicine. http://

15. The Guardian, "ANC urged to deliver Aids drugs" (2010).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology Europe,
Click here